198 related articles for article (PubMed ID: 23528733)
21. Determinants of tetherin antagonism in the transmembrane domain of the human immunodeficiency virus type 1 Vpu protein.
Vigan R; Neil SJ
J Virol; 2010 Dec; 84(24):12958-70. PubMed ID: 20926557
[TBL] [Abstract][Full Text] [Related]
22. βTrCP is Required for HIV-1 Vpu Modulation of CD4, GaLV Env, and BST-2/Tetherin.
Song YE; Cyburt D; Lucas TM; Gregory DA; Lyddon TD; Johnson MC
Viruses; 2018 Oct; 10(10):. PubMed ID: 30347660
[TBL] [Abstract][Full Text] [Related]
23. Modulation of HIV-1-host interaction: role of the Vpu accessory protein.
Dubé M; Bego MG; Paquay C; Cohen ÉA
Retrovirology; 2010 Dec; 7():114. PubMed ID: 21176220
[TBL] [Abstract][Full Text] [Related]
24. Role of the endocytic pathway in the counteraction of BST-2 by human lentiviral pathogens.
Lau D; Kwan W; Guatelli J
J Virol; 2011 Oct; 85(19):9834-46. PubMed ID: 21813615
[TBL] [Abstract][Full Text] [Related]
25. HIV-1 Vpu utilizes both cullin-RING ligase (CRL) dependent and independent mechanisms to downmodulate host proteins.
Ramirez PW; DePaula-Silva AB; Szaniawski M; Barker E; Bosque A; Planelles V
Retrovirology; 2015 Jul; 12():65. PubMed ID: 26215564
[TBL] [Abstract][Full Text] [Related]
26. Vpu-mediated tetherin antagonism of ongoing HIV-1 infection in CD4(+) T-cells is not directly related to the extent of tetherin cell surface downmodulation.
Kuhl BD; Sloan RD; Donahue DA; Liang C; Wainberg MA
Virology; 2011 Sep; 417(2):353-61. PubMed ID: 21757214
[TBL] [Abstract][Full Text] [Related]
27. Human tetherin exerts strong selection pressure on the HIV-1 group N Vpu protein.
Sauter D; Unterweger D; Vogl M; Usmani SM; Heigele A; Kluge SF; Hermkes E; Moll M; Barker E; Peeters M; Learn GH; Bibollet-Ruche F; Fritz JV; Fackler OT; Hahn BH; Kirchhoff F
PLoS Pathog; 2012 Dec; 8(12):e1003093. PubMed ID: 23308067
[TBL] [Abstract][Full Text] [Related]
28. Vpu augments the initial burst phase of HIV-1 propagation and downregulates BST2 and CD4 in humanized mice.
Sato K; Misawa N; Fukuhara M; Iwami S; An DS; Ito M; Koyanagi Y
J Virol; 2012 May; 86(9):5000-13. PubMed ID: 22357275
[TBL] [Abstract][Full Text] [Related]
29. Efficient BST2 antagonism by Vpu is critical for early HIV-1 dissemination in humanized mice.
Dave VP; Hajjar F; Dieng MM; Haddad É; Cohen ÉA
Retrovirology; 2013 Nov; 10():128. PubMed ID: 24195843
[TBL] [Abstract][Full Text] [Related]
30. FRET Analysis of the Promiscuous yet Specific Interactions of the HIV-1 Vpu Transmembrane Domain.
Cole GB; Reichheld SE; Sharpe S
Biophys J; 2017 Nov; 113(9):1992-2003. PubMed ID: 29117523
[TBL] [Abstract][Full Text] [Related]
31. Vpu of a Simian Immunodeficiency Virus Isolated from Greater Spot-Nosed Monkey Antagonizes Human BST-2 via Two AxxxxxxxW Motifs.
Yao W; Yoshida T; Hashimoto S; Takeuchi H; Strebel K; Yamaoka S
J Virol; 2020 Jan; 94(2):. PubMed ID: 31666374
[TBL] [Abstract][Full Text] [Related]
32. Lack of adaptation to human tetherin in HIV-1 group O and P.
Yang SJ; Lopez LA; Exline CM; Haworth KG; Cannon PM
Retrovirology; 2011 Sep; 8():78. PubMed ID: 21955466
[TBL] [Abstract][Full Text] [Related]
33. Vpu directs the degradation of the human immunodeficiency virus restriction factor BST-2/Tetherin via a {beta}TrCP-dependent mechanism.
Douglas JL; Viswanathan K; McCarroll MN; Gustin JK; Früh K; Moses AV
J Virol; 2009 Aug; 83(16):7931-47. PubMed ID: 19515779
[TBL] [Abstract][Full Text] [Related]
34. β-TrCP is dispensable for Vpu's ability to overcome the CD317/Tetherin-imposed restriction to HIV-1 release.
Tervo HM; Homann S; Ambiel I; Fritz JV; Fackler OT; Keppler OT
Retrovirology; 2011 Feb; 8():9. PubMed ID: 21310048
[TBL] [Abstract][Full Text] [Related]
35. Polarity changes in the transmembrane domain core of HIV-1 Vpu inhibits its anti-tetherin activity.
Lv M; Wang J; Wang X; Zuo T; Zhu Y; Kong W; Yu X
PLoS One; 2011; 6(6):e20890. PubMed ID: 21674066
[TBL] [Abstract][Full Text] [Related]
36. HIV-1 Nef and Vpu Interfere with L-Selectin (CD62L) Cell Surface Expression To Inhibit Adhesion and Signaling in Infected CD4+ T Lymphocytes.
Vassena L; Giuliani E; Koppensteiner H; Bolduan S; Schindler M; Doria M
J Virol; 2015 May; 89(10):5687-700. PubMed ID: 25822027
[TBL] [Abstract][Full Text] [Related]
37. Counteraction of tetherin antiviral activity by two closely related SIVs differing by the presence of a Vpu gene.
Nikovics K; Dazza MC; Ekwalanga M; Mammano F; Clavel F; Saragosti S
PLoS One; 2012; 7(4):e35411. PubMed ID: 22530020
[TBL] [Abstract][Full Text] [Related]
38. Cell Surface Downregulation of NK Cell Ligands by Patient-Derived HIV-1 Vpu and Nef Alleles.
Galaski J; Ahmad F; Tibroni N; Pujol FM; Müller B; Schmidt RE; Fackler OT
J Acquir Immune Defic Syndr; 2016 May; 72(1):1-10. PubMed ID: 26656785
[TBL] [Abstract][Full Text] [Related]
39. The ESCRT-0 component HRS is required for HIV-1 Vpu-mediated BST-2/tetherin down-regulation.
Janvier K; Pelchen-Matthews A; Renaud JB; Caillet M; Marsh M; Berlioz-Torrent C
PLoS Pathog; 2011 Feb; 7(2):e1001265. PubMed ID: 21304933
[TBL] [Abstract][Full Text] [Related]
40. BST-2 is rapidly down-regulated from the cell surface by the HIV-1 protein Vpu: evidence for a post-ER mechanism of Vpu-action.
Skasko M; Tokarev A; Chen CC; Fischer WB; Pillai SK; Guatelli J
Virology; 2011 Mar; 411(1):65-77. PubMed ID: 21237475
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
